Background Adoptive cell transfer (ACT) is a promising cancer immunotherapeutic strategy
that remains ineffective for a large subset of patients. ACT with memory CD8+ T cells (T …

Adoptive cell transfer (ACT) melanoma immunotherapy typically employs acutely activated
effector CD8+ T cells for their ability to rapidly recognize and clear antigen. We have …

Adoptive immunotherapy using ex vivo–expanded tumor-reactive lymphocytes can mediate
durable cancer regression in selected melanoma patients. Analyses of these trials have …

Purpose: Adoptive cell transfer (ACT) of tumor infiltrating or genetically engineered T cells
can cause durable responses in patients with metastatic cancer. Multiple clinically …

Background Adoptive cell transfer (ACT) immunotherapy has been used clinically for years
to treat malignancies. Improving the killing efficiency of effector cells, such as tumor-specific …

Adoptive immunotherapy with cytotoxic T cells has shown promising clinical results in
patients with metastatic melanoma and post-transplant-associated viral infections. However …

Cancer immunotherapy using the adoptive transfer of autologous tumor-infiltrating
lymphocytes results in objective cancer regression in 49–72% of patients with metastatic …

The optimal T-cell attributes for adoptive cancer immunotherapy are unclear. Recent clinical
trials of ex vivo–expanded tumor-infiltrating lymphocytes indicated that differentiated T …

Adoptive transfer of tumor-reactive T cells has emerged as a promising advance in tumor
immunotherapy. Specifically, infusion of tumor-infiltrating lymphocytes has led to long-term …

Immunotherapy holds a highly promising treatment approach for metastatic melanoma
patients. Adoptive cell transfer (ACT) involves the ex vivo expansion of autologous antitumor …